… adverse effects of doxycycline and minocycline, no divergence was shown in … -induced
thyroid pigment and several synthetic models: identification and characterization by electron …

… Paldino et al. demonstrated that these R6/2 mice exposed to doxycycline survived longer
and restored neurological dysfunction compared to saline-treated ones. Doxycycline …

… , anti-M3AR did not cause morphological changes in that in vitro model, while anti-SPCA1 …
including mitochondrion-protecting agents (minocycline or doxycycline 200 mg/day + …

… memory in fly models of Alzheimer’s disease [35]. In mammalian models, NDGA prevents
Aβ … Aβ deposition and brain amyloidosis in transgenic mice with Alzheimer’s disease [36]. …

… derivatives, minocycline (90) and doxycycline (91), exhibit effective neuroprotective activity
in experimental models of neurodegenerative/neuropsychiatric diseases and no substantial …

… Similarly, in the APP/PS1 mouse model of Alzheimer's disease, murine NSCs increased …
Parallel findings were likewise found using a model of Huntington's disease treated with human …

… minocycline and doxycycline are lipophilic agents with good … models of multiple sclerosis
[127, 128], Huntington disease [129, … Most recent studies suggest the utility of minocycline in the …

… has not been elucidated yet. The current model explaining antibiotics’ beneficial features is
… and derivatives, such as doxycycline and minocycline, as neuroprotector antibiotics through …

… creating opportunities to recapitulate disease phenotypes that are not otherwise accessible.
… brain organoid models for the study of many different types of human neurological disorders …

… trials undertaken to assess possible clinical benefits of tetracyclines in the treatment of
AD (minocycline; NCT01463384) or transthyretin amyloidosis (doxycycline; NCT01677286). …